Meta-regression showed a reduced efficacy of SGLT2 inhibitors in preventing AF when more patients with HFmrEF or HFpEF were included (β = 0.006, P = 0.003) and with higher LVEF (β = 0.021, P = 0.004). This evidence concerns the gene SLC5A2 and atrial fibrillation.